Hørsdal Oskar Kjærgaard, Ellegaard Mark Stoltenberg, Larsen Alexander Møller, Guldbrandsen Halvor, Moeslund Niels, Møller Jacob Eifer, Helgestad Ole Kristian Lerche, Ravn Hanne Berg, Wiggers Henrik, Nielsen Roni, Gopalasingam Nigopan, Berg-Hansen Kristoffer
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Department of Cardiology, Aarhus University Hospital, Palle Juul Jensens Boulevard 99, 8200, Aarhus, Denmark.
Crit Care. 2025 Mar 14;29(1):113. doi: 10.1186/s13054-025-05346-2.
Cardiogenic shock (CS) is associated with high mortality and medical therapies have failed to improve survival. Treatment with lactate is associated with improved cardiac function which may benefit this condition. Comprehensive hemodynamic assessment of lactate administration in CS is lacking, and the mechanisms underlying the cardiovascular effects of lactate in CS have not yet been elucidated. In this study we aimed to study the cardiovascular and cardiometabolic effects of treatment with lactate in experimental ischemic CS.
In a randomized, blinded design, 20 female pigs (60 kg) were studied. Left main coronary artery microsphere injections were used to cause CS, defined as a 30% reduction in CO or mixed venous saturation (SvO). Subjects were randomized to receive either intravenous exogenous lactate or euvolemic, equimolar saline (control) for 180 min. Positive inotropic control with dobutamine was administered on top of ongoing treatment after 180 min. Extensive hemodynamic measurements were obtained from pulmonary artery and left ventricular (LV) pressure-volume catheterization. Furthermore, endomyocardial biopsies were analyzed for mitochondrial function and arterial, renal vein, and coronary sinus blood samples were collected. The primary endpoint was change in CO during 180 min of treatment.
Arterial lactate levels increased from 2.4 ± 1.1 to 7.7 ± 1.1 mmol/L (P < 0.001) during lactate infusion. CO increased by 0.7 L/min (P < 0.001) compared with control, due to increased stroke volume (P = 0.003). Notably, heart rate and mean arterial pressure did not differ significantly between treatments. End-systolic elastance (load independent contractility) was enhanced during lactate infusion (P = 0.048), together with LV ejection fraction (P = 0.009) and dP/dt(max) (P = 0.041). Arterial elastance (afterload) did not differ significantly (P = 0.12). This resulted in improved ventriculo-arterial coupling efficiency (P = 0.012). Cardiac mechanical efficiency (P = 0.003), diuresis (P = 0.016), and SvO (P = 0.018) were increased during lactate infusion. Myocardial mitochondrial complex I respiration was enhanced during lactate infusion compared with control (P = 0.04). Concomitant administration of dobutamine on top of lactate resulted in further hemodynamic improvements compared with control.
Lactate infusion improved cardiac function and myocardial mitochondrial respiration in a porcine model of CS. The hemodynamic effects included increased CO mediated through stroke volume increase. These favorable cardiovascular effects may benefit patients with CS.
心源性休克(CS)死亡率高,药物治疗未能改善生存率。乳酸治疗可改善心脏功能,可能对这种情况有益。目前缺乏对CS中乳酸给药的全面血流动力学评估,且CS中乳酸对心血管作用的潜在机制尚未阐明。在本研究中,我们旨在研究实验性缺血性CS中乳酸治疗对心血管和心脏代谢的影响。
采用随机、盲法设计,对20只雌性猪(60千克)进行研究。通过左冠状动脉主干注射微球诱导CS,定义为心输出量(CO)或混合静脉血氧饱和度(SvO)降低30%。将受试者随机分为静脉注射外源性乳酸组或等容、等摩尔生理盐水组(对照组),持续180分钟。180分钟后,在持续治疗的基础上给予多巴酚丁胺进行正性肌力控制。通过肺动脉和左心室(LV)压力-容积导管插入术进行广泛的血流动力学测量。此外,分析心内膜活检的线粒体功能,并采集动脉、肾静脉和冠状窦血样。主要终点是治疗180分钟期间CO的变化。
乳酸输注期间,动脉血乳酸水平从2.4±1.1毫摩尔/升增至7.7±1.1毫摩尔/升(P<0.001)。与对照组相比,CO增加了0.7升/分钟(P<0.001),这归因于每搏输出量增加(P=0.003)。值得注意的是,各治疗组之间心率和平均动脉压无显著差异。乳酸输注期间,心脏收缩末期弹性(负荷无关收缩性)增强(P=0.048),同时左心室射血分数(P=0.009)和dP/dt(max)(P=0.041)也增强。动脉弹性(后负荷)无显著差异(P=0.12)。这导致心室-动脉耦合效率提高(P=0.012)。乳酸输注期间,心脏机械效率(P=0.003)、尿量(P=0.016)和SvO(P=0.018)增加。与对照组相比,乳酸输注期间心肌线粒体复合物I呼吸增强(P=0.04)。与对照组相比,在乳酸基础上联合使用多巴酚丁胺可进一步改善血流动力学。
在CS猪模型中,乳酸输注可改善心脏功能和心肌线粒体呼吸。血流动力学效应包括通过增加每搏输出量介导的CO增加。这些有利的心血管效应可能使CS患者受益。